Medical equipment major Edwards Lifesciences Corporation (EW - Analyst Report) recently announced the receipt of CE Mark for its Acumen Hypotension Probability Indicator (HPI). The device is an advanced technology that alerts clinicians of potential hypotension or abnormally low blood pressure in surgical and critical care patients.
HPI is used with Edwards Lifesciences' minimally invasive hemodynamic (blood flow) monitoring solution dubbed as FloTrac IQ sensor which recently gained CE mark. HPI is likely to be available in Europe later this year with a full launch planned for 2017. It is not approved for commercial use in the U.S.
The indicator has three features, the first being hypotension probability parameter, which indicates the possibility of a hypotensive event .Secondly, the device has an alarm that notifies clinicians when the hypotensive event may cross the upper limit. And then there is a secondary screen that visually connects blood pressure to hemodynamic flow parameters, such as cardiac output and contractility. The whole system helps clinicians accurately identify and detect hypotension conditions in patients. As per University College London, studies have shown that even limited durations of hypotension can be lethal for patients.
As per a Medgadget report, the critical care equipment market is expected to reach a worth of $2.61 billion, growing at a CAGR of 8.0% by 2021. We feel that Edwards Lifesciences is trying to tap in on this growing market.
Edwards Lifesciences has been performing well in its critical care device segment for quite some time now. In the second quarter of 2016, the company reported sales of $142 million, which improved 7% on an underlying basis at this segment. Meanwhile, the CE mark for HPI is going to help the company expand in the critical care equipment market in Europe.
Zacks Rank & Key Picks
Edwards Lifesciences currently has a Zacks Rank #2 (Buy). Other favorably ranked stocks in the medical product sector are GW Pharmaceuticals plc (GWPH - Analyst Report) , Quidel Corp. (QDEL - Snapshot Report) and NuVasive, Inc. (NUVA - Analyst Report) . GW Pharmaceuticals and Quidel sport a Zacks Rank #1 (Strong Buy) while NuVasive carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals recorded a 91.73% gain year to date, far better than the S&P 500’s 5.21% over the same time frame. The trailing four-quarter average earning surprise is 41.67%.
Quidel gained 14.50% in the past one year, higher than the S&P 500’s 8.61%. Over the next five years, the stock is estimated to record earnings growth rate of 20%, higher than the industry average of 14.8%.
NuVasive surged 27.29% over the past one year compared to the S&P 500’s 8.61%. Over the next five years, the stock is expected to see 16.7% earnings growth compared to the industry average of 14.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>